Intermittent Claudication

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 12 54 43 15 37 71
Amyotrophic Lateral Sclerosis 71
Charcot's Syndrome 12
Charcot Disease 74


External Ids:

Disease Ontology 12 DOID:3669
MeSH 43 D007383
SNOMED-CT 67 63491006
ICD10 32 I73.9
UMLS 71 C0002736 C0021775

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as amyotrophic lateral sclerosis, is related to peripheral artery disease and angina pectoris, and has symptoms including seizures, polydipsia and fatigue. An important gene associated with Intermittent Claudication is SELP (Selectin P), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Pioglitazone and Vorapaxar have been mentioned in the context of this disorder. Affiliated tissues include Placenta, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Charcot-Marie-Tooth disease (CMT) is a hereditary motor and sensory neuropathies of the peripheral... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 756)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.1 VWF VEGFA SELP IL6 IGF1 CRP
2 angina pectoris 31.6 IL6 CRP ACE
3 raynaud phenomenon 31.0 VWF HTR2A APOH
4 lipid metabolism disorder 30.9 SERPINE1 IL6 CRP ACE
5 coronary heart disease 1 30.9 VWF SERPINE1 SELP IL6 CRP ACE
6 arteries, anomalies of 30.8 VWF VEGFA SERPINE1 IL6 CRP ALB
7 arteriosclerosis 30.8 SERPINE1 SERPINC1 SELP IL6 IL10 CRP
8 aortic aneurysm, familial abdominal, 1 30.6 IL6 CRP ACE
9 raynaud disease 30.6 CRP CD40LG ACE
10 peripheral vascular disease 30.5 VWF VEGFA SERPINE1 SERPINC1 SELP PF4
11 carotid stenosis 30.5 VEGFA SELP IL10 CRP ACE
12 carotid artery disease 30.5 VWF SELP IL6 CRP ACE
13 generalized atherosclerosis 30.5 VWF SERPINE1 IL6 CRP ALB ACE
14 polyarteritis nodosa 30.5 SELP IL6 CRP APOH
15 amyloidosis 30.4 IL6 CRP CD40LG ALB
16 systolic heart failure 30.4 VWF IL6 CRP ACE
17 compartment syndrome 30.4 SERPINC1 IL6 F2 CRP ALB
18 congestive heart failure 30.4 VEGFA IL6 CRP ANGPT2 ALB ACE
19 temporal arteritis 30.4 IL6 CRP CD40LG APOH
20 polycythemia vera 30.3 VWF SELP PF4 F2
21 atherosclerosis susceptibility 30.3 VWF VEGFA SERPINE1 SELP IL6 CRP
22 bone resorption disease 30.3 IL6 IGF1 CRP ALB
23 thrombophilia due to thrombin defect 30.3 SERPINE1 SERPINC1 PF4 F2 APOH
24 common cold 30.2 SELP IL6 IL10 ALB
25 limb ischemia 30.2 VWF VEGFA TEK SERPINE1 PGF IL6
26 pulmonary tuberculosis 30.2 IL6 IL10 CRP ALB
27 intermediate coronary syndrome 30.1 VWF SERPINC1 SELP PF4 IL6 CRP
28 protein s deficiency 30.1 SERPINE1 SERPINC1 F2 APOH
29 varicose veins 30.1 VWF VEGFA SERPINC1 IL6 F2
30 protein c deficiency 30.1 SERPINE1 SERPINC1 F2 APOH
31 chlamydia pneumonia 30.0 IL6 IL10 CRP CD40LG
32 chlamydia 30.0 IL6 IL10 CRP CD40LG
33 coronary stenosis 30.0 VWF SERPINE1 IL6 CRP ALB ACE
34 hemangioma 30.0 VWF VEGFA TEK F2 ANGPT2
35 glucose intolerance 29.9 SERPINE1 IL6 IGF1 CRP ALB ACE
36 cerebrovascular disease 29.9 VWF SERPINE1 SELP IL6 F2 CRP
37 thrombophilia due to activated protein c resistance 29.7 VWF SERPINE1 SERPINC1 PF4 F2 APOH
38 infective endocarditis 29.7 SERPINE1 PF4 IL6 F2 CRP APOH
39 scoliosis 29.7 VWF IL6 IGF1 ALB ACE
40 glycogen storage disease 29.7 VWF IGF1 CRP ALB
41 deficiency anemia 29.6 SERPINC1 SELP IL6 IGF1 CRP ALB
42 bronchitis 29.6 VEGFA IL6 IL10 CRP CD40LG ALB
43 thrombophilia 29.4 VWF SERPINE1 SERPINC1 SELP PF4 F2
44 vasculitis 29.3 VWF SELP IL6 IL10 CRP CD40LG
45 hypothyroidism 29.3 VWF VEGFA SERPINE1 IGF1 F2 CRP
46 thrombophlebitis 29.1 VWF SERPINE1 SERPINC1 SELP F2 CRP
47 exanthem 29.1 VEGFA IL6 IL10 F2 CRP CD40LG
48 peripheral nervous system disease 29.1 VEGFA IL6 IL10 IGF1 CRP CD40LG
49 thrombosis 29.1 VWF SERPINE1 SERPINC1 SELP PF4 F2
50 rheumatoid arthritis 29.0 VEGFA TEK IL6 IL10 CRP CD40LG

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):

Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:

Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:

seizures, polydipsia, fatigue, edema, tremor, back pain, headache, syncope, cyanosis, pain, chills, chronic pain, asthenia, sciatica, signs and symptoms, signs and symptoms, digestive, hot flushes, vertigo/dizziness, sleeplessness, signs and symptoms, respiratory, oral manifestations, eye manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, skin manifestations, renal colic, mobility limitation, prodromal symptoms, medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 ACE ALB ANGPT2 CD40LG COL18A1 CRP
2 homeostasis/metabolism MP:0005376 10.43 ACE ALB ANGPT2 APOH CD40LG COL18A1
3 immune system MP:0005387 10.31 ACE ALB ANGPT2 CD40LG CRP F2
4 hematopoietic system MP:0005397 10.29 ACE CD40LG F2 IGF1 IL10 IL6
5 mortality/aging MP:0010768 10.2 ACE ALB ANGPT2 APOH CD40LG F2
6 digestive/alimentary MP:0005381 10.1 ALB ANGPT2 F2 HTR2A IL10 IL6
7 integument MP:0010771 10.1 ANGPT2 CD40LG F2 IGF1 IL10 IL6
8 liver/biliary system MP:0005370 9.97 ACE ALB IL10 IL6 SELP SERPINC1
9 neoplasm MP:0002006 9.91 ACE ALB COL18A1 IGF1 IL10 IL6
10 renal/urinary system MP:0005367 9.85 ACE ALB CD40LG COL18A1 IGF1 IL6
11 respiratory system MP:0005388 9.61 ANGPT2 F2 IGF1 IL10 IL6 PGF
12 vision/eye MP:0005391 9.28 ANGPT2 COL18A1 IL10 IL6 PGF SELP

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 441)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Vorapaxar Approved Phase 4 618385-01-6
Thrombin Approved, Investigational Phase 4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Losartan Approved Phase 4 114798-26-4 3961
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
Glimepiride Approved Phase 4 93479-97-1 3476
Gliclazide Approved Phase 4 21187-98-4 3475
Glyburide Approved Phase 4 10238-21-8 3488
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Capsaicin Approved Phase 4 404-86-4 1548943
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
Allopurinol Approved Phase 4 315-30-0 2094
Ramipril Approved Phase 4 87333-19-5 5362129
Glucagon Approved Phase 4 16941-32-5
Liraglutide Approved Phase 4 204656-20-2 44147092
Evolocumab Approved Phase 4 1256937-27-5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
Rivaroxaban Approved Phase 4 366789-02-8
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Metformin Approved Phase 4 657-24-9 14219 4091
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
Candesartan Experimental Phase 4 139481-59-7 2541
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
35 Analgesics, Non-Narcotic Phase 4
36 Analgesics Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Antirheumatic Agents Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Central Nervous System Stimulants Phase 4
41 Anti-Anxiety Agents Phase 4
42 Mitogens Phase 4
43 Calcium, Dietary Phase 4
44 calcium channel blockers Phase 4
45 Cyclooxygenase Inhibitors Phase 4
46 Dermatologic Agents Phase 4
47 calcium heparin Phase 4
48 carnitine Phase 4
49 Antipyretics Phase 4
50 Endothelial Growth Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 958)
# Name Status NCT ID Phase Drugs
1 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
2 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
3 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
4 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
5 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
6 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
7 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
8 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
9 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
10 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex). Completed NCT00300690 Phase 4
11 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
12 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
13 A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication Completed NCT00887744 Phase 4
14 Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study Completed NCT00614926 Phase 4 Modafinil;Placebo
15 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
16 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
17 A Double Blind, Randomised, Placebo Controlled Trial to Study the Clinical and Cost Effectiveness of the Angiotensin Converting Enzyme Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
18 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
19 A Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™ System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis With Neurogenic Intermittent Claudication Completed NCT00905359 Phase 4
20 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
21 Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS Completed NCT00409747 Phase 4 Minocycline
22 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
23 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
24 The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function Completed NCT00660634 Phase 4
25 Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial Completed NCT00715416 Phase 4
26 4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
27 A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
28 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
29 ACE Inhibition; A Potential New Therapy for Peripheral Arterial Disease Completed NCT00681226 Phase 4 Ramipril or matching placebo
30 Evaluation of Motor Unit Abnormalities After Experimentally Induced Sensitization Using Capsaicin: A Randomized, Double-Blinded, Placebo-Controlled Study Completed NCT04361149 Phase 4 Capsaicin Topical Cream (0.075%)
31 Effects of Cilostazol on Vascular Endothelial Growth Factor , Inflammatory and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease. Completed NCT00431249 Phase 4 Cilostazol
32 Balloon Angioplasty Versus Stenting With Nitinol Stents in the Superficial Femoral Artery Completed NCT00281060 Phase 4
33 The Effects of Physical Training, Aspirin, and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease Completed NCT00189618 Phase 4 Aspirin;Clopidogrel
34 Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration Recruiting NCT04107740 Phase 4 C-Trelin OD Tab(5mg Taltirelin Hydrate);Placebo
35 Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease. Recruiting NCT02983214 Phase 4 Clopidogrel;Cilostazol
36 Liraglutide Efficacy and Action on Type 2 Diabetes With Peripheral Atherosclerotic intErmittent Claudication (LEADPACE STUDY): a Prospective, 24-week, Multicenter, Randomized, Controlled Clinical Study Recruiting NCT04146155 Phase 4 Liraglutide+standard-of-care treatment
37 Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease (Evol-PAD) Recruiting NCT04306081 Phase 4 Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months.
38 Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis Recruiting NCT02842424 Phase 4 Ramipril
39 DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease. Not yet recruiting NCT04218656 Phase 4 Rivaroxaban 2.5 Mg Oral Tablet
40 A Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Pentoxifylline or Placebo in Addition to Standard of Care for Treatment of Proteinuria in Patients With Lupus Nephritis. Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
41 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Terminated NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
42 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
43 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
44 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Terminated NCT01901224 Phase 4 Metformin 1000 mg;Placebo
45 Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR) Terminated NCT02374957 Phase 4 Cilostazol
46 A Clinical Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant in Comparison With the Best Non-operative Treatment of Lumbar Spine Stenosis Terminated NCT01057641 Phase 4
47 Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients Terminated NCT00517751 Phase 4
48 Prospective Randomized Trial Comparing X-STOP® Interspinous Process Decompression® System Versus Laminectomy for Treatment of Neurogenic Intermittent Claudication Withdrawn NCT00558129 Phase 4
49 A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients Withdrawn NCT02121288 Phase 4 Ticagrelor;clopidogrel
50 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion. A Prospective Randomized Trial Comparing Silverhawk™ Atherectomy to CryoPlasty® Therapy for Lower Extremity Claudication Withdrawn NCT00407940 Phase 4

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

Testes, Brain, Bone, Endothelial, Heart, Skeletal Muscle, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 4919)
# Title Authors PMID Year
Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. 61 54
15649725 2005
Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. 61 54
15033248 2004
Platelet activation is increased in peripheral arterial disease. 54 61
12844097 2003
Platelets' glycoproteins and their ligands in patients with intermittent claudication. 61 54
12865882 2003
Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. 54 61
11958389 2001
Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. 54 61
11448424 2001
New treatment options in intermittent claudication: the US experience. 54 61
11355276 2001
Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. 54 61
11455059 2001
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. 54 61
11028477 2000
Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 54 61
9423790 1997
Repeated exercise induces release of soluble P-selectin in patients with intermittent claudication. 61 54
9408015 1997
Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication. 54 61
1752890 1991
Collapse of VBX Balloon-Expandable Endoprosthesis in Bilateral Common Iliac Arteries in a Lean, Elderly Patient with Bent Back. 61
32018024 2020
Patients undergoing interventions for claudication experience low perioperative morbidity but are at risk for worsening functional status and limb loss. 61
31839346 2020
The Medical and Endovascular Treatment of PAD: A Review of the Guidelines and Pivotal Clinical Trials. 61
30573160 2020
Arterial Reconstruction for Patients with Chronic Limb Ischemia Improves Ambulatory Function and Health-related Quality of Life. 61
32035265 2020
Current and emerging drug treatment strategies for peripheral arterial disease. 61
32558590 2020
Serum Metabolic Signatures of Chronic Limb-Threatening Ischemia in Patients with Peripheral Artery Disease. 61
32560175 2020
Knowledge of peripheral artery disease: What do the public, healthcare practitioners, and trainees know? 61
32000617 2020
Impact of obesity on walking capacity and cardiovascular parameters in patients with peripheral artery disease: A cross-sectional study. 61
32534655 2020
Influence of preprocedural glycemic control on clinical outcomes of endovascular therapy in diabetic patients with lower extremity artery disease: an analysis from a Korean multicenter retrospective registry cohort. 61
32571352 2020
Relationship Between Disease Specific Quality of Life Measures, Physical Performance, and Activity in People with Intermittent Claudication Caused by Peripheral Artery Disease. 61
32336621 2020
NT5E Genetic Mutation Is a Rare But Important Cause of Intermittent Claudication and Chronic Limb-Threatening Ischemia. 61
32522903 2020
A Comparison of Quality of Life in Elderly Patients with Intermittent Claudication and Chronic Limb-Threatening Ischemia. 61
32502674 2020
Response to Letter Regarding Article, "Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial". 61
32519878 2020
Letter by Ng and Choong Regarding Article, "Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial". 61
32519891 2020
miR-378a influences vascularization in skeletal muscles. 61
31504257 2020
Filum Terminale Arteriovenous Fistula in Association with Degenerative Lumbosacral Spinal Canal Stenosis: Report of 3 Cases and Review of the Literature. 61
32169619 2020
Telephone health coaching with exercise monitoring using wearable activity trackers (TeGeCoach) for improving walking impairment in peripheral artery disease: study protocol for a randomised controlled trial and economic evaluation. 61
32503866 2020
Role of aorto(bi)femoral bypass in treatment of patients with critical limb threatening ischemia. 61
32507455 2020
Lower limb venous and arterial peripheral diseases and work conditions: systematic review. 61
32439829 2020
National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. 61
31699514 2020
Vascular Regeneration in Peripheral Artery Disease. 61
32434408 2020
Paclitaxel and Mortality Following Peripheral Angioplasty: An Adjusted and Case Matched Multicentre Analysis. 61
32370918 2020
Cilostazol Mediates Immune Responses and Affects Angiogenesis During the Acute Phase of Hind Limb Ischemia in a Mouse Model. 61
31906705 2020
Impact of Institutional Volume on Critical In-Hospital Complications Adjusted for Patient- and Limb-Related Characteristics: An Analysis of a Nationwide Japanese Registry of Endovascular Interventions for PAD. 61
32436810 2020
Mitochondrial DNA copy number is associated with all-cause mortality and cardiovascular events in patients with peripheral arterial disease. 61
32037598 2020
Low Risk of Procedure Related Major Amputation Following Revascularisation for Intermittent Claudication: A Population Based Study. 61
31866238 2020
Funicular pain: a case report of intermittent claudication induced by cervical cord compression. 61
32410709 2020
Randomized controlled trial of vacuum therapy for intermittent claudication. 61
31690523 2020
Prevalence and Risk Factors of Peripheral Arterial Disease in Patients with Lumbar Spinal Stenosis and Intermittent Claudication: CT Angiography Study. 61
32242344 2020
An exploratory study of vibration therapy on muscle function in patients with peripheral artery disease. 61
31619350 2020
The importance of FDG PET/CT in the diagnostic process of the middle aortic syndrome in a 15-year-old boy patient with suspected systemic vasculitis and final diagnosis of Williams-Beuren syndrome. 61
32239321 2020
Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. 61
32252582 2020
Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis. 61
31926836 2020
Improved Oral Pharmacokinetics of Pentoxifylline with Palm Oil and Capmul® MCM Containing Self-Nano-Emulsifying Drug Delivery System. 61
32318890 2020
Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study. 61
31983287 2020
Concomitant Revascularization Using Ascending Aortic Rerouting in Coral Reef Aortic Syndrome. 61
31669483 2020
[Principles of angiology in lower extremity arterial disease (LEAD)]. 61
32140731 2020
Analysis of haemodynamics and angiogenic response to ischaemia in the obese type 2 diabetic model Spontaneously Diabetic Torii Leprfa (SDT fatty) rats. 61
31868944 2020

Variations for Intermittent Claudication

Copy number variations for Intermittent Claudication from CNVD:

# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107025 17 11200000 22100000 Microduplication Charcot

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

Pathways related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
13.29 TEK PGF PF4 IL6 IL10 IGF1
Show member pathways
13.13 TEK PGF PF4 IL6 IL10 IGF1
Show member pathways
Show member pathways
Show member pathways
12.48 TEK IL6 IL10 F2 ANGPT2
Show member pathways
Show member pathways
11 12.07 VEGFA IL6 IL10 HTR2A
Show member pathways
Show member pathways
15 11.9 VEGFA IL6 IGF1 ALB
Show member pathways
11.56 VEGFA IL6 CD40LG
18 11.55 SELP IL10 CD40LG
19 11.42 VEGFA IL6 IGF1
20 11.26 SELP IL6 IL10 CD40LG
22 10.51 TEK PGF PF4 IL6 IL10 IGF1

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VWF VEGFA TEK SERPINE1 SERPINC1 PGF
2 collagen-containing extracellular matrix GO:0062023 9.86 VWF SERPINE1 SERPINC1 PF4 F2 COL18A1
3 endoplasmic reticulum lumen GO:0005788 9.72 SERPINC1 IL6 F2 COL18A1 ALB
4 platelet alpha granule lumen GO:0031093 9.63 VWF VEGFA SERPINE1 PF4 IGF1 ALB
5 extracellular space GO:0005615 9.55 VEGFA SERPINE1 SERPINC1 SELP PGF PF4

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.27 VEGFA TEK PGF IL6 IL10 IGF1
2 positive regulation of gene expression GO:0010628 10.07 VEGFA PF4 IL6 IGF1 CRP
3 inflammatory response GO:0006954 10.04 SELP PF4 IL6 CRP CD40LG
4 leukocyte migration GO:0050900 9.95 TEK SELP F2 ANGPT2
5 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TEK PGF F2
6 positive regulation of cell proliferation GO:0008284 9.95 VEGFA PGF IL6 IGF1 HTR2A F2
7 cellular response to lipopolysaccharide GO:0071222 9.93 SERPINE1 PF4 IL6 IL10
8 cellular protein metabolic process GO:0044267 9.92 SERPINC1 IL6 IGF1 F2 ALB
9 response to hypoxia GO:0001666 9.91 VEGFA TEK PGF ANGPT2
10 negative regulation of apoptotic process GO:0043066 9.91 VEGFA TEK IL6 IL10 IGF1 CD40LG
11 negative regulation of angiogenesis GO:0016525 9.87 TEK PF4 APOH ANGPT2
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 VEGFA IL6 IGF1
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 VEGFA IL6 IGF1 HTR2A
14 hemostasis GO:0007599 9.81 VWF SERPINC1 F2
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 TEK SELP IGF1 F2
16 positive regulation of endothelial cell proliferation GO:0001938 9.78 VEGFA TEK PGF IL10
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.76 TEK SERPINE1 IL10
18 acute-phase response GO:0006953 9.75 IL6 F2 CRP
19 sprouting angiogenesis GO:0002040 9.73 VEGFA TEK PGF
20 positive regulation of JAK-STAT cascade GO:0046427 9.72 IL6 IL10 F2
21 positive regulation of angiogenesis GO:0045766 9.72 VEGFA TEK SERPINE1 PGF ANGPT2
22 negative regulation of lipid storage GO:0010888 9.67 IL6 CRP
23 blood coagulation, intrinsic pathway GO:0007597 9.67 VWF F2 APOH
24 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.66 IGF1 APOH
25 neutrophil mediated immunity GO:0002446 9.65 IL6 ACE
26 positive regulation of mast cell chemotaxis GO:0060754 9.63 VEGFA PGF
27 positive regulation of blood coagulation GO:0030194 9.63 SERPINE1 F2 APOH
28 angiogenesis GO:0001525 9.63 VEGFA TEK SERPINE1 PGF COL18A1 ANGPT2
29 negative regulation of MHC class II biosynthetic process GO:0045347 9.62 PF4 IL10
30 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.61 VEGFA ACE
31 regulation of blood coagulation GO:0030193 9.61 SERPINC1 F2 APOH
32 glomerulus vasculature development GO:0072012 9.6 TEK ANGPT2
33 Tie signaling pathway GO:0048014 9.59 TEK ANGPT2
34 negative regulation of fibrinolysis GO:0051918 9.43 SERPINE1 F2 APOH
35 platelet activation GO:0030168 9.35 VWF PF4 IL6 F2 CD40LG
36 platelet degranulation GO:0002576 9.23 VWF VEGFA SERPINE1 SELP PF4 IGF1

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 VWF VEGFA TEK SERPINE1 SERPINC1 SELP
2 identical protein binding GO:0042802 9.81 VWF VEGFA TEK SERPINC1 PGF HTR2A
3 cytokine activity GO:0005125 9.65 VEGFA PF4 IL6 IL10 CD40LG
4 drug binding GO:0008144 9.58 HTR2A ALB ACE
5 growth factor activity GO:0008083 9.43 VEGFA PGF IL6 IL10 IGF1 F2
6 vascular endothelial growth factor receptor binding GO:0005172 9.37 VEGFA PGF
7 heparin binding GO:0008201 9.17 VEGFA SERPINC1 SELP PGF PF4 F2

Sources for Intermittent Claudication

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....